Hipertensão arterial pulmonar associada à anemia falciforme

Translated title of the contribution: Sickle cell anemia-associated pulmonary arterial hypertension

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Pulmonary hypertension is a common complication of sickle cell anemia. Despite the fact that the elevations in pulmonary artery pressures are slight, morbidity and mortality are high. In adult sickle cell anemia patients, pulmonary hypertension is emerging as a major risk factor for death. The pathogenesis of sickle cell anemia-related pulmonary hypertension is multifactorial, including hemolysis, impaired nitric oxide bioavailability, chronic hypoxemia, thromboembolism, chronic liver disease and asplenia. In the majority of patients, pulmonary arterial hypertension is the main cause of elevated pulmonary artery pressures. However, pulmonary venous hypertension also plays a role in a subgroup of patients. Specific data on the effects of treatment modalities for pulmonary hypertension in patients with sickle cell anemia are scarce. It is likely that all patients would benefit from maximization of sickle cell anemia therapy, and that patients with the severe form of the disease would benefit from treatment with selective pulmonary vasodilators and antiproliferative agents. Large trials evaluating the effects of treatment for pulmonary hypertension in the sickle cell anemia population are underway.

Original languagePortuguese
Pages (from-to)583-591
Number of pages9
JournalJornal Brasileiro de Pneumologia
Volume33
Issue number5
DOIs
StatePublished - Sep 1 2007
Externally publishedYes

Fingerprint

Sickle Cell Anemia
Pulmonary Hypertension
Pulmonary Artery
Pressure
Thromboembolism
Cell- and Tissue-Based Therapy
Hemolysis
Vasodilator Agents
Biological Availability
Liver Diseases
Nitric Oxide
Chronic Disease
Therapeutics
Morbidity
Lung
Mortality
Population

Keywords

  • Anemia, sickle cell
  • Hemolysis
  • Hypertension, pulmonary
  • Nitric oxide

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Hipertensão arterial pulmonar associada à anemia falciforme. / Machado, Roberto.

In: Jornal Brasileiro de Pneumologia, Vol. 33, No. 5, 01.09.2007, p. 583-591.

Research output: Contribution to journalReview article

@article{68d7421296514280acec8f0b9fb609c1,
title = "Hipertens{\~a}o arterial pulmonar associada {\`a} anemia falciforme",
abstract = "Pulmonary hypertension is a common complication of sickle cell anemia. Despite the fact that the elevations in pulmonary artery pressures are slight, morbidity and mortality are high. In adult sickle cell anemia patients, pulmonary hypertension is emerging as a major risk factor for death. The pathogenesis of sickle cell anemia-related pulmonary hypertension is multifactorial, including hemolysis, impaired nitric oxide bioavailability, chronic hypoxemia, thromboembolism, chronic liver disease and asplenia. In the majority of patients, pulmonary arterial hypertension is the main cause of elevated pulmonary artery pressures. However, pulmonary venous hypertension also plays a role in a subgroup of patients. Specific data on the effects of treatment modalities for pulmonary hypertension in patients with sickle cell anemia are scarce. It is likely that all patients would benefit from maximization of sickle cell anemia therapy, and that patients with the severe form of the disease would benefit from treatment with selective pulmonary vasodilators and antiproliferative agents. Large trials evaluating the effects of treatment for pulmonary hypertension in the sickle cell anemia population are underway.",
keywords = "Anemia, sickle cell, Hemolysis, Hypertension, pulmonary, Nitric oxide",
author = "Roberto Machado",
year = "2007",
month = "9",
day = "1",
doi = "10.1590/S1806-37132007000500015",
language = "Portuguese",
volume = "33",
pages = "583--591",
journal = "Jornal Brasileiro de Pneumologia",
issn = "1806-3713",
publisher = "Sociedade Brasileira de Pneumologia e Tisiologia",
number = "5",

}

TY - JOUR

T1 - Hipertensão arterial pulmonar associada à anemia falciforme

AU - Machado, Roberto

PY - 2007/9/1

Y1 - 2007/9/1

N2 - Pulmonary hypertension is a common complication of sickle cell anemia. Despite the fact that the elevations in pulmonary artery pressures are slight, morbidity and mortality are high. In adult sickle cell anemia patients, pulmonary hypertension is emerging as a major risk factor for death. The pathogenesis of sickle cell anemia-related pulmonary hypertension is multifactorial, including hemolysis, impaired nitric oxide bioavailability, chronic hypoxemia, thromboembolism, chronic liver disease and asplenia. In the majority of patients, pulmonary arterial hypertension is the main cause of elevated pulmonary artery pressures. However, pulmonary venous hypertension also plays a role in a subgroup of patients. Specific data on the effects of treatment modalities for pulmonary hypertension in patients with sickle cell anemia are scarce. It is likely that all patients would benefit from maximization of sickle cell anemia therapy, and that patients with the severe form of the disease would benefit from treatment with selective pulmonary vasodilators and antiproliferative agents. Large trials evaluating the effects of treatment for pulmonary hypertension in the sickle cell anemia population are underway.

AB - Pulmonary hypertension is a common complication of sickle cell anemia. Despite the fact that the elevations in pulmonary artery pressures are slight, morbidity and mortality are high. In adult sickle cell anemia patients, pulmonary hypertension is emerging as a major risk factor for death. The pathogenesis of sickle cell anemia-related pulmonary hypertension is multifactorial, including hemolysis, impaired nitric oxide bioavailability, chronic hypoxemia, thromboembolism, chronic liver disease and asplenia. In the majority of patients, pulmonary arterial hypertension is the main cause of elevated pulmonary artery pressures. However, pulmonary venous hypertension also plays a role in a subgroup of patients. Specific data on the effects of treatment modalities for pulmonary hypertension in patients with sickle cell anemia are scarce. It is likely that all patients would benefit from maximization of sickle cell anemia therapy, and that patients with the severe form of the disease would benefit from treatment with selective pulmonary vasodilators and antiproliferative agents. Large trials evaluating the effects of treatment for pulmonary hypertension in the sickle cell anemia population are underway.

KW - Anemia, sickle cell

KW - Hemolysis

KW - Hypertension, pulmonary

KW - Nitric oxide

UR - http://www.scopus.com/inward/record.url?scp=41549129901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41549129901&partnerID=8YFLogxK

U2 - 10.1590/S1806-37132007000500015

DO - 10.1590/S1806-37132007000500015

M3 - Review article

VL - 33

SP - 583

EP - 591

JO - Jornal Brasileiro de Pneumologia

JF - Jornal Brasileiro de Pneumologia

SN - 1806-3713

IS - 5

ER -